12:35 , May 8, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

New Therapeutic Targets and Biomarkers: April 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April. Therapeutic targets are defined as any protein, gene or other molecule...
13:53 , Apr 10, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting bacterial RelA to enhance isoniazid sensitivity in tuberculosis

DISEASE CATEGORY: Infectious disease INDICATION: Tuberculosis Cell culture and mouse studies suggest inhibiting M. tuberculosis RelA could help treat chronic-phase tuberculosis (TB), which is resistant to the generic antimalarial isoniazid. In an M. tuberculosis culture-based...
23:17 , Oct 3, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: September 2018

New Therapeutic Targets and Biomarkers: September 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in September. Therapeutic targets are defined as any protein, gene or other molecule...
17:35 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Pseudomonas Cell culture studies suggest inhibition of P. aeruginosa sodB or combined inhibition of P. aeruginosa relA and spoT could help treat chronic infections by the bacteria and prevent drug resistance. In stationary-phase P....
03:28 , Jan 19, 2018 |  BC Innovations  |  Tools & Techniques

Synthetic expressions

Bringing synthetic biology to transcriptional regulation could catalyze a new generation of gene therapies that are more tunable, disease-specific and easy to deliver than the products dominating the field. The new constructs include synthetic promoters...
07:00 , Oct 2, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Rheumatoid arthritis (RA) v-Rel reticuloendotheliosis viral oncogene homolog A (RELA; p65) Mouse studies suggest peptide-siRNA nanocomplexes targeting p65 could help treat RA and other...
07:00 , Mar 27, 2014 |  BC Innovations  |  Targets & Mechanisms

Insights into ependymoma

Two independent studies have illuminated the fine molecular details of ependymoma tumors and identified targets for a previously intractable disease. A St. Jude Children's Research Hospital team focused on forebrain ependymomas and identified a fusion...
07:00 , Mar 13, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer V-rel reticuloendotheliosis viral oncogene homolog A (RELA; p65); chromosome 11 open reading frame 95 (C11orf95) Patient sample and cell culture studies suggest targeting...
08:00 , Feb 18, 2013 |  BC Week In Review  |  Clinical News

CAT-1004: Phase I data

A 3-part, double-blind, placebo-controlled, U.S. Phase I trial in 105 healthy volunteers or Type II diabetics showed that oral CAT-1004 was well tolerated. Additionally, a single dose of CAT-1004 in healthy volunteers led to a...
07:00 , Oct 11, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Gram-positive bacterial infection GTP pyrophosphokinase (relA) In vitro studies identified an inhibitor of relA that could help treat Gram-positive bacterial infections. relA synthesizes (p)ppGpp,...